Kiromic BioPharma Announces Hiring of FTI Consulting
Houston, Texas, Oct. 12, 2017 — Kiromic BioPharma Inc., today announced that it will be hiring the global business advisory firm, FTI Consulting, to support and advice on upcoming public relations initiatives.
About Kiromic BioPharma
Kiromic is a clinical-stage immuno-oncology biopharmaceutical company with a breakthrough artificial intelligence called KAI, and drug discovery programs across multiple technology platforms; including cellular therapies, TCR therapy, and CAR-T therapy, oral immunotherapy, and gene therapy.
Kiromic is committed to developing effective immunotherapeutics to improve outcomes and dramatically improve patient’s lives.
For more information, visit www.kiromic.com.
About FTI Consulting
FTI Consulting, Inc. is an international business advisory firm with a strong track-record of assisting organizations in managing public relations, political & regulatory matters, mitigating risk, and resolving disputes.
For more information, visit www.fticonsulting.com.
Kiromic BioPharma Announces New Board Member
Kiromic BioPharma welcomes Peter Hoang to its Board of Directors, who brings a wealth of experience in the biotechnology sector to his role as a Director for the company. Peter is currently President & Chief Executive Officer and a member of the Board of Directors of TapImmune (Nasdaq: TPIV) a clinical-stage immuno-oncology company with ongoing clinical trials at the Mayo Clinic and Memorial Sloan-Kettering Cancer Center. Prior to TapImmune, he served as the Senior Vice President of Business Development & Strategy at Bellicum Pharmaceuticals (Nasdaq: BLCM), a clinical stage immuno-oncology and cell therapy company developing small molecule-controllable gene-modified T cell-based therapeutics. Previously, Peter led the new venture formation and development effort as the Managing Director, Innovations in the Strategic Industry Ventures department for The University of Texas MD Anderson Cancer Center. In addition to his executive management experience leading publicly traded biotechnology companies, Peter has over 18 years of finance and deal-making experience in investment banking and venture capital, advising on over 100 transactions with an aggregate deal value of over $120 billion. Prior to MD Anderson, Peter was a senior investment banker, most recently as Managing Director and head of global healthcare mergers & acquisitions advisory for CIT Group (NYSE: CIT). He has also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch and Deutsche Bank.